Klaudia Kwiatkowska

Klaudia Kwiatkowska

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
THTomasz Horodniczy
Tomasz Horodniczy
KKKlaudia Kwiatkowska
Klaudia Kwiatkowska
KCKamila Chęcińska
Kamila Chęcińska
Maciej ChęcińskiMaciej Chęciński
Maciej Chęciński
KGKarolina Grzybowska-Kowalczyk
Karolina Grzybowska-Kowalczyk
Maciej SikoraMaciej Sikora
Maciej Sikora
Background/Objectives: Ultrasound is increasingly used to guide minimally invasive interventions for temporomandibular joint (TMJ) disorders because it enables real-time visualization of the joint, surrounding tissues, and needle position. This scoping review aimed to map and characterize the available evidence on ultrasound-guided minimally invasive interventions for temporomandibular disorders (TMDs). Methods: The review followed PRISMA-ScR guidelines and was registered in the Open Science Framework (osf.io/r42m5). PubMed/MEDLINE, BASE, and Europe PMC were searched up to 4 April 2026. Original clinical and technical studies evaluating ultrasound-guided minimally invasive interventions for TMDs were included. Results: Seventeen studies published between 2012 and 2026 met the eligibility criteria. Ultrasound guidance was used mainly for intra-articular injections, arthrocentesis, and botulinum toxin injections into the lateral pterygoid muscle. Most studies reported reductions in pain and improvements in jaw function. Compared with conventional approaches, several included studies reported more accurate needle placement, fewer insertion attempts, less need for needle repositioning, and shorter procedure times when ultrasound guidance was used. However, these procedural advantages did not consistently translate into superior long-term clinical outcomes. Conclusions: Overall, ultrasound-guided minimally invasive TMJ interventions appear feasible and generally safe, with their main benefit being improved visualization and procedural precision. Further standardized, high-quality studies are needed to clarify their clinical impact.

30 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMaja Kosinska
Maja Kosinska
Maciej ChęcińskiMaciej Chęciński
Maciej Chęciński
WMWojciech Macek
Wojciech Macek
KKKlaudia Kwiatkowska
Klaudia Kwiatkowska
KGKarolina Grzybowska-Kowalczyk
Karolina Grzybowska-Kowalczyk
Maciej SikoraMaciej Sikora
Maciej Sikora
Background/Objectives: This scoping review mapped how hyaluronic acid (HA) molecular weight has been defined and investigated in direct clinical comparisons for temporomandibular disorders (TMDs), including formulations, populations, procedures, outcomes, and methodological limitations. Methods: Final searches and selection were completed on 9 September 2026 using PubMed, BASE, CENTRAL, and Europe PMC. Prospective human studies comparing different intra-articular HA preparations under the same procedural protocol were eligible, including matched comparisons within multi-arm studies. Two reviewers independently screened and charted the evidence. Findings were synthesized descriptively without meta-analysis or formal risk-of-bias assessment. The protocol was registered in OSF (osf.io/sc8wv). Results: Five reports were included: three quasi-randomized trials and two prospective studies with sequential or unreported allocation between HA formulations. Four reported efficacy comparisons; one contributed safety data only after swelling and marked pain in 2 of 5 recipients prompted discontinuation of a high-molecular-weight arm. Molecular-weight categories overlapped across reports, formulation characteristics were incompletely reported, and protocols varied from one to five injections with differing use of arthrocentesis. Comparative follow-up ranged from 3 to 12 months. No eligible efficacy comparison detected a statistically significant difference, but small samples, allocation limitations, and incomplete subgroup reporting restricted interpretation. Conclusions: The evidence map identifies inconsistent formulation classification, procedural heterogeneity, and deficiencies in outcome and safety reporting as barriers to interpretation. It does not establish equivalence, superiority, or comparative safety of molecular-weight categories and provides specific priorities for future studies.